Deutsche Bank Ag\ Forte Biosciences, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 11, 2022	SELL	$1.07 - $1.55 $38,813 - $56,224	-36,274 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.21 - $2.24 $33,608 - $62,218	-27,776 Reduced 43.37%	36,274 $53,000
Q4 2021 Feb 11, 2022	BUY	$2.02 - $3.36 $112,857 - $187,723	55,870 Added 683.01%	64,050 $137,000
Q3 2021 Nov 04, 2021	SELL	$2.96 - $36.67 $6,423 - $79,573	-2,170 Reduced 20.97%	8,180 $24,000
Q2 2021 Aug 11, 2021	BUY	$31.5 - $42.5 $227,115 - $306,425	7,210 Added 229.62%	10,350 $348,000
Q3 2020 Nov 12, 2020	SELL	$14.71 - $50.69 $3,530 - $12,165	-240 Reduced 7.1%	3,140 $152,000
Q2 2020 Aug 13, 2020	BUY	$13.9 - $24.6 $46,982 - $83,148	3,380 New	3,380 $49,000

Others Institutions Holding FBRX

# of Institutions

1

Shares Held

175K

Call Options Held

0

Put Options Held

0

Black Rock Inc. New York, NY

175K
Shares

$977,456
0.0% of portfolio

About Forte Biosciences, Inc.

Ticker FBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,340,300
Market Cap $114M
Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

More about FBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.